1-Test Cyp 100

1-Test Cyp 100 Dragon Pharma — Overview

1-Test Cyp 100 Dragon Pharma is injectable Dihydroboldenone Cypionate (DHB) at 100 mg/ml — a 5α-reduced derivative of boldenone with an anabolic-to-androgenic ratio of approximately 200:100, making it twice as anabolic as testosterone on a milligram-per-milligram basis while maintaining an equivalent androgenic load. The cypionate ester provides a half-life of approximately 8–10 days, enabling a twice-weekly injection schedule comparable to Testosterone Cypionate. DHB aromatizes minimally due to its 5α-reduced structure, producing dry, quality lean mass gains without the estrogenic water retention associated with testosterone or boldenone. It does not convert further to DHT, carries no progestin activity, and has no hepatotoxic pathway as an injectable compound. One characteristic defines DHB above all others for practical use: it produces among the most severe post-injection pain (PIP) of any injectable AAS currently available, requiring active management protocols before every administration. Steroid Warehouse carries 1-Test Cyp 100 Dragon Pharma for intermediate and advanced users who understand both the compound's anabolic advantage and its injection management requirements.

About the Compound: Dihydroboldenone Cypionate (DHB)

• Structural origin: 5α-reduced boldenone — DHB (1-testosterone, dihydroboldenone) is the 5α-reduced metabolite of boldenone (Equipoise); the 5α-reduction removes the double bond at the 1,2-position that boldenone retains, producing a compound with the same C-17 hydroxyl group and undecylenate-equivalent structural activity but with the DHT-class resistance to further metabolism; the cypionate ester at C-17 in Dragon Pharma's formulation extends the half-life to approximately 8–10 days, creating a twice-weekly injectable with stable plasma kinetics comparable to Testosterone Cypionate but with a fundamentally different anabolic profile
• Why the anabolic ratio is ~200 and what that means — the 200:100 anabolic-to-androgenic ratio is derived from rat levator ani muscle assay data, the standard preclinical model for AAS potency comparison; it means DHB produces approximately twice the anabolic tissue stimulus per milligram compared to testosterone in assay conditions; in practice this translates to meaningful lean mass accrual at doses (200–400 mg/week) that are half the milligram load of comparable testosterone cycles, while the androgenic and estrogenic exposures remain proportionally lower; the practical result is quality lean gains with minimal water retention and a manageable hormonal side effect profile relative to the anabolic output
• Aromatization: minimal but not zero — 5α-reduced steroids do not undergo efficient aromatization because the 5α-reduction closes the A-ring in a way that sterically prevents CYP19A1 (aromatase) from acting on the substrate; DHB aromatizes at a very low rate, producing minimal E2 elevation at standard doses; however, at doses of 400 mg/week or in users with high baseline aromatase activity, low-grade E2 accumulation can occur over a 12–16 week cycle; a low prophylactic AI dose or E2 monitoring at mid-cycle is reasonable rather than high-dose AI management
• PIP (post-injection pain): the defining practical limitation — DHB consistently produces the most severe post-injection pain reported among commonly used injectable AAS; the mechanism is multi-factorial: the high polarity of the dihydroboldenone free acid relative to the carrier oil creates a large surface energy mismatch at the injection depot, triggering local inflammatory response disproportionate to the steroid concentration; the pain typically begins 12–24 hours post-injection, peaks at 24–48 hours, and may persist for 3–7 days depending on the individual, the injection volume, and whether mitigation protocols were followed; PIP management is not optional — see Side Effects & Management for mandatory protocols

What 1-Test Cyp 100 Does

• Lean, dry anabolic mass accrual — DHB's twice-testosterone anabolic ratio, combined with minimal aromatization, produces the characteristic dry lean mass gains the compound is known for; gains accumulate gradually and consistently without the first-week water weight spike common to testosterone or Dianabol cycles; the lean tissue deposited during a DHB cycle is high quality — it is retained well post-cycle because it is not dependent on estrogenic water retention; a 12-week cycle at 300 mg/week typically produces 5–8 kg of net lean mass in well-trained users running a caloric surplus, with minimal post-cycle water loss compared to equivalent testosterone cycles
• Strength gains without mass-to-strength lag — the androgen receptor binding affinity of DHB drives strength output commensurate with its anabolic rating; users consistently report strength progression throughout the cycle without the disproportionate strength-to-size ratio that characterizes some high-aromatization compounds where water-mediated strength gains precede actual hypertrophy; the strength gains from DHB are structural in origin and correlate with the lean mass accrued, making them more durable post-cycle
• Low estrogenic and progestogenic burden — because DHB does not aromatize appreciably and has no progestin activity, the estrogen-mediated and progesterone-mediated side effect profile is substantially lower than testosterone at equivalent anabolic doses; gynecomastia risk is low, water retention is minimal, and blood pressure elevation from estrogenic water retention is reduced; this makes DHB well-suited for stacking with compounds that themselves carry estrogenic load (e.g., Testosterone Cypionate as a base), where DHB contributes the majority of the anabolic stimulus while the testosterone base manages the small aromatization baseline
• Hardening and conditioning effect — the absence of estrogenic water retention combined with the androgenic stimulus to subcutaneous fat reduction gives DHB a conditioning effect analogous to Masteron or Primobolan; in a caloric deficit or at maintenance calories, DHB produces visible improvement in muscle density and vascularity, making it a practical pre-contest compound or a lean bulk tool for users who prioritize physique quality over maximum mass accumulation

Who It's For

• Key differentiator from comparable dry-gaining compounds — DHB's combination of a ~200 anabolic rating with minimal aromatization is unique among the Dragon Pharma injectable lineup; Masteron 200 has a low anabolic rating (~62) and is primarily a hardening and anti-estrogenic tool rather than a mass builder; Primobolan 100 offers quality dry gains at an anabolic rating of ~88; Trenbolone 200 exceeds DHB in potency but adds 19-Nor-class cardiovascular, androgenic, and progestin-related sides absent from DHB; DHB occupies the specific position of highest anabolic rating among the low-aromatization injectable options, with a side effect ceiling meaningfully lower than Trenbolone
• Best scenario — intermediate to advanced users running lean bulk or pre-contest cycles who want the anabolic output of a high-potency compound without the estrogenic water retention of testosterone at equivalent doses; users who have already optimized testosterone-based cycles and want to add a dry anabolic layer without 19-Nor progestin risk; users running Testosterone Cypionate as their base who want to add a mechanistically distinct anabolic compound in the same injection schedule (both have ~8–10 day half-life and twice-weekly administration)
• Choose something else instead — users unwilling or unable to implement active PIP management protocols on every injection should choose Primobolan 100 Dragon Pharma or Masteron 200 Dragon Pharma for comparable low-aromatization injectable gains without the PIP burden; first-cycle and second-cycle users should not use DHB as their primary anabolic compound; users with low pain tolerance or injection anxiety should avoid DHB regardless of experience level; users whose primary goal is maximum mass gain should use higher-aromatization compounds where estrogenic water retention contributes to total scale weight

DHB vs Alternatives

Combinations

Side Effects & Management

Bloodwork Monitoring

Post-Cycle Recovery

DHB's cypionate ester has a half-life of approximately 8–10 days; near-complete clearance occurs within 3 weeks of the last injection. SERM begins 2 weeks after the last injection, with HCG bridging during the clearance window.

For full PCT timing context, see the PCT guide.

Practical Summary

DHB (Dihydroboldenone Cypionate) is a compound defined by a specific trade-off: the highest anabolic rating among the low-aromatization injectable options in the Dragon Pharma lineup, at the cost of requiring the most active injection management protocol of any AAS in the same category. For intermediate and advanced users who implement the PIP mitigation protocols correctly, steroidwarehouse.com's 1-Test Cyp 100 delivers quality lean mass accrual and a dry, hard physique outcome that neither Masteron 200 nor Primobolan 100 can match on an equivalent per-week dose basis.

References